Rib-X touts positive PhIIb antibiotic data

Rib-X Pharmaceuticals, which is mounting an $80 million IPO effort, is touting positive midstage data from the Phase IIb study of its antibiotic delafloxacin. "Delafloxacin met or exceeded primary and secondary efficacy endpoints evaluated to date in comparison to Zyvox (linezolid), with and without aztreonam, and vancomycin, with and without aztreonam, including endpoints based on the draft guidance" from the FDA, the biotech says. The positive outcome positions Rib-X--a 2011 Fierce 15 company--to take the antibiotic into Phase III. The biotech has burned through $238 million in its quest to develop new antibiotics and recently signed a development pact with Sanofi ($SNY). Release

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.